Skip to content
10-K

Annual Report

Dare Bioscience, Inc. DARE

0001401914-26-000004

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 25, 2026 14.56M sh
Shares Diluted FY 2025 · Dec 31, 2025 11.18M sh
Shares Diluted FY 2025 · Dec 31, 2024 8.5M sh
Capex FY 2025 · Dec 31, 2025 $385.28K
Capex FY 2025 · Dec 31, 2024 $573.05K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$9.89M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 $5.47M
Cash And Equivalents FY 2025 · Dec 31, 2025 $24.71M
Cash And Equivalents FY 2025 · Dec 31, 2024 $15.7M
Stockholders Equity FY 2025 · Dec 31, 2025 $2.84M
Stockholders Equity FY 2025 · Dec 31, 2024 −$6.01M
Stockholders Equity FY 2025 · Dec 31, 2023 −$5.05M
Current Liabilities FY 2025 · Dec 31, 2025 $23.69M
Current Liabilities restated FY 2025 · Dec 31, 2024 $21.61M
Total Liabilities FY 2025 · Dec 31, 2025 $29.63M
Total Liabilities FY 2025 · Dec 31, 2024 $28.11M
Current Assets FY 2025 · Dec 31, 2025 $27.06M
Current Assets FY 2025 · Dec 31, 2024 $18.45M
Total Assets FY 2025 · Dec 31, 2025 $32.47M
Total Assets FY 2025 · Dec 31, 2024 $22.1M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.20
Eps Diluted FY 2025 · Dec 31, 2024 −$0.48
Eps Basic FY 2025 · Dec 31, 2025 −$1.20
Eps Basic FY 2025 · Dec 31, 2024 −$0.48
Sga Expense FY 2025 · Dec 31, 2025 $8.76M
Sga Expense FY 2025 · Dec 31, 2024 $9.16M
Rd Expense FY 2025 · Dec 31, 2025 $5.52M
Rd Expense restated FY 2025 · Dec 31, 2024 $14.31M
Net Income FY 2025 · Dec 31, 2025 −$13.4M
Net Income FY 2025 · Dec 31, 2024 −$4.05M
Operating Income FY 2025 · Dec 31, 2025 −$13.55M
Operating Income FY 2025 · Dec 31, 2024 −$23.45M
Cost Of Revenue FY 2025 · Dec 31, 2025 $295.8K
Cost Of Revenue FY 2025 · Dec 31, 2024 $0
Revenue FY 2025 · Dec 31, 2025 $1.03M
Revenue FY 2025 · Dec 31, 2024 $9.78K